



Dynavax Technologies Corporation  
Investor Relations Department  
2929 Seventh Street  
Berkeley, CA 94710  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: DVAX

|               |                             |
|---------------|-----------------------------|
| Last Trade:   | 15.38                       |
| Trade Time:   | 10:36 AM ET<br>Jan 16, 2018 |
| Change:       | -0.37  (-2.375%)            |
| Day Range     | 14.65 - 15.78               |
| 52-Week Range | 3.70 - 24.45                |
| Volume        | 892,274                     |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Jan 12, 2018

[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Jan 8, 2018

[Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults](#)

Jan 4, 2018

[Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference](#)

Dec 5, 2017

[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Nov 27, 2017

[Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Jul 10, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017

[Quarterly Report \(10-Q\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)